Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, FDA
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage signaling that the company has succeeded in expanding manufacturing.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications.
Eli Lilly's shortage of diabetes and obesity drugs is over, halting competition with knock-offs
Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, freeing the company from competing with compounding pharmacies that have been producing copycat versions of the in-demand treatments.
2d
Lilly looking to test Zepbound as health maintenance drug: report
Eli Lilly (LLY) is reportedly looking to study its weight-loss drug Zepbound in people who aren't considered overweight but ...
19h
on MSN
Here’s Why Eli Lilly and Company (LLY) Surged in Q2
PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...
1d
Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements
Eli Lilly is pouring another $4.5 billion into expanding drug manufacturing and development. The diabetes treatment maker ...
1d
Mounjaro and Zepbound no longer in shortage
After nearly two years, federal regulators announced the shortage of the active ingredient in Mounjaro and Zepbound has been ...
FiercePharma
1d
High-flying Eli Lilly pushes more chips forward with $4.5B 'Medicine Foundry' project
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
ConsumerAffairs
14h
Mountjaro, Zepbound removed from FDA's shortage list
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
21h
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback